Leaflet edge-to-edge treatment versus direct annuloplasty in patients for functional mitral regurgitation.

AIMS Interventional mitral repair techniques have evolved as safe and effective treatment options for patients with functional mitral regurgitation (FMR) at high or prohibitive surgical risk. Of the techniques available, the MitraClip device and Cardioband mitral repair system have been used most commonly. However, a direct comparison of the two devices, examining their effectiveness at reducing MR, reducing symptoms, and extending life expectancy, has not yet been performed. For this purpose, we compared the outcome of patients after direct annuloplasty by the Cardioband system with patients after edge-to-edge therapy with the MitraClip device in a propensity score-matched analysis. METHODS AND RESULTS We collected data concerning 123 consecutive patients who were treated with the Cardioband device and 455 consecutive patients treated with the MitraClip from five experienced European centres. Propensity score matching was performed, resulting in two groups with 93 patients each - with no significant differences regarding baseline demographic parameters - who underwent standardised 2D transthoracic echocardiography with assessment at baseline and clinical follow-up at 12 months. The success rate, defined as a reduction of MR to grade 2 or lower, was high in both groups (MR ≤2: MitraClip: 86%, Cardioband: 77%, p=0.18). The Cardioband was better at reducing heart failure symptoms (NYHA ≤II: 88%) than the MitraClip (75%) procedure (p=0.046) at 12-month follow-up. All-cause rehospitalisation and mortality within 12 months were lower in Cardioband patients (mortality: OR 0.30, CI: 0.09-0.98, p=0.032; rehospitalisation: OR 0.57, CI: 0.28-0.97, p=0.03). CONCLUSIONS The MitraClip and the Cardioband procedures effectively reduce MR and heart failure symptoms. However, patients undergoing the Cardioband procedure showed a more pronounced improvement with regard to functional NYHA class, rehospitalisation, and mortality, compared to patients undergoing the MitraClip procedure.

[1]  A. Sannino,et al.  Proportionate and Disproportionate Functional Mitral Regurgitation: A New Conceptual Framework That Reconciles the Results of the MITRA-FR and COAPT Trials. , 2019, JACC. Cardiovascular imaging.

[2]  K. Kuck,et al.  Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes , 2018, European heart journal.

[3]  P. Voisine,et al.  Transcatheter Mitral-Valve Repair in Patients with Heart Failure. , 2019, The New England journal of medicine.

[4]  D. Adams,et al.  Isolated Mitral Valve Surgery: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis. , 2018, The Annals of thoracic surgery.

[5]  D. Maucort-Boulch,et al.  Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation , 2018, The New England journal of medicine.

[6]  Helmut Baumgartner,et al.  [2017 ESC/EACTS Guidelines for the management of valvular heart disease]. , 2017, Kardiologia polska.

[7]  L. Fleisher,et al.  2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[8]  O. Alfieri,et al.  Cardioband, a transcatheter surgical-like direct mitral valve annuloplasty system: early results of the feasibility trial. , 2016, European heart journal.

[9]  P. Boekstegers,et al.  One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry , 2015, European heart journal.

[10]  M. Mack,et al.  Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II. , 2015, Journal of the American College of Cardiology.

[11]  G. Filippatos,et al.  Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 2: Endpoint Definitions: A Consensus Document From the Mitral Valve Academic Research Consortium. , 2015, Journal of the American College of Cardiology.

[12]  Antonio Colombo,et al.  The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs. replacement? , 2015, European heart journal.

[13]  O. Alfieri,et al.  First-in-man transseptal implantation of a "surgical-like" mitral valve annuloplasty device for functional mitral regurgitation. , 2014, JACC. Cardiovascular interventions.

[14]  J. Hausleiter,et al.  Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. , 2013, Journal of the American College of Cardiology.

[15]  J. Zamorano,et al.  Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. , 2013, European heart journal cardiovascular Imaging.

[16]  Jennifer Taylor,et al.  ESC/EACTS Guidelines on the management of valvular heart disease. , 2012, European heart journal.

[17]  Scott Lim,et al.  Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. , 2009, Journal of the American College of Cardiology.

[18]  E. Foster,et al.  Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST Phase I Clinical Trial. , 2005, Journal of the American College of Cardiology.